<SEC-DOCUMENT>0001513162-16-001098.txt : 20161207
<SEC-HEADER>0001513162-16-001098.hdr.sgml : 20161207
<ACCEPTANCE-DATETIME>20161207064216
ACCESSION NUMBER:		0001513162-16-001098
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20161207
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20161207
DATE AS OF CHANGE:		20161207

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ITUS Corp
		CENTRAL INDEX KEY:			0000715446
		STANDARD INDUSTRIAL CLASSIFICATION:	PATENT OWNERS & LESSORS [6794]
		IRS NUMBER:				112622630
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1031

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37492
		FILM NUMBER:		162037592

	BUSINESS ADDRESS:	
		STREET 1:		12100 WILSHIRE BOULEVARD
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90025
		BUSINESS PHONE:		31044845200

	MAIL ADDRESS:	
		STREET 1:		12100 WILSHIRE BOULEVARD
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COPYTELE INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<head><title>form 8K</title> </head> <body lang=EN-US> <div style=page:WordSection1> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman","serif"'>UNITED STATES</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman","serif"'>SECURITIES AND EXCHANGE COMMISSION</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman","serif"'>Washington, D.C. 20549</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><u><font style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></u></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman","serif"'>FORM 8-K</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman","serif"'>CURRENT REPORT</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman","serif"'>Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman","serif"'>Date of Report (Date of earliest event reported):&nbsp; December 7, 2016</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><u></u></b>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><u><font style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman","serif"'>ITUS CORPORATION</font></u></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman","serif"'>(Exact name of registrant as specified in its charter)</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <div align=center> <table width=733 bordercolor=transparent style="WIDTH:550pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr> <td width=194 style="WIDTH:145.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman","serif"'>Delaware</font></b></p></td> <td width=175 style="WIDTH:130.95pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=top> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman","serif"'>000-11254</font></b></p></td> <td width=170 style="WIDTH:127.45pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=top> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman","serif"'>11-2622630</font></b></p></td></tr> <tr> <td width=194 style="WIDTH:145.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=top> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman","serif"'>(State or other jurisdiction<br>of incorporation)</font></p></td> <td width=175 style="WIDTH:130.95pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=top> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman","serif"'>(Commission<br>File Number)</font></p></td> <td width=170 style="WIDTH:127.45pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=top> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman","serif"'>(IRS Employer</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman","serif"'>Identification No.)</font></p></td></tr></table></div> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; MARGIN:0in 0in 0pt'>&nbsp;</p> <div align=center> <table width=733 bordercolor=transparent style="WIDTH:550pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr> <td width=349 style="WIDTH:261.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman","serif"'>12100 Wilshire Boulevard, Suite 1275</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman","serif"'>Los Angeles, CA</font></b></p></td> <td width=337 style="WIDTH:252.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman","serif"'>90025</font></b></p></td></tr> <tr> <td width=349 style="WIDTH:261.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman","serif"'>(Address of principal executive offices)</font></p></td> <td width=337 style="WIDTH:252.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman","serif"'>(Zip Code)</font></p></td></tr></table></div> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman","serif"'>Registrant&#146;s telephone number, including area code:&nbsp; <b>(310) 484-5200</b></font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; MARGIN:0in 0in 0pt'><font style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; </font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman","serif"'>(Former name or former address, if changed since last report)</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><u><font style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></u></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; PAGE-BREAK-AFTER:auto; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><u></u></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><a name=up><font style=FONT-SIZE:11pt>Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:<br><br></font></a></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt 0.5in; TEXT-INDENT:-0.5in'><font style=FONT-SIZE:11pt><font face=Wingdings>o</font>&nbsp;&nbsp;&nbsp; Written communications pursuant to Rule&nbsp;425 under the Securities Act (17&nbsp;CFR&nbsp;230.425)</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt 0.5in; TEXT-INDENT:-0.5in'><font style=FONT-SIZE:11pt><font face=Wingdings>o </font>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17&nbsp;CFR&nbsp;240.14a-12)</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt 0.5in; TEXT-INDENT:-0.5in'><font style=FONT-SIZE:11pt><font face=Wingdings>o </font>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17&nbsp;CFR&nbsp;240.14d-2(b))</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt 0.5in; TEXT-INDENT:-0.5in'><font style=FONT-SIZE:11pt><font face=Wingdings>o </font>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17&nbsp;CFR&nbsp;240.13e-4(c))</font></p></div><b><font style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman","serif"'><br clear=all></font></b> <div style=page:WordSection2> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b> <hr style=PAGE-BREAK-AFTER:always> </b></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b>Item 8.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Events<br></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; TEXT-INDENT:0.5in'><font style=FONT-SIZE:11pt><br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ITUS Corporation issued a press release announcing Cchek</font><font style="FONT-SIZE:11pt; FONT-FAMILY:Symbol">&#212;</font><font style=FONT-SIZE:11pt>&nbsp;preliminary cancer patient efficacy study results. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:11pt><br>Item 9.01 Financial Statements and Exhibits.</font></b></p><pre style="FONT-SIZE:11pt; FONT-FAMILY:Courier; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style='FONT-FAMILY:"Times New Roman","serif"'><br> (d) Exhibits</font></pre><pre style="FONT-SIZE:11pt; FONT-FAMILY:Courier; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;</font></pre><pre style="FONT-SIZE:11pt; FONT-FAMILY:Courier; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style='FONT-FAMILY:"Times New Roman","serif"'>The following exhibits are filed with this Current Report on Form 8-K:</font></pre><pre style="FONT-SIZE:11pt; FONT-FAMILY:Courier; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;</font></pre><pre style="FONT-SIZE:11pt; FONT-FAMILY:Courier; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style='FONT-FAMILY:"Times New Roman","serif"'>Exhibit No.&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;Description</font></pre><pre style="FONT-SIZE:11pt; FONT-FAMILY:Courier; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;</font></pre><pre style="FONT-SIZE:11pt; FONT-FAMILY:Courier; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style='FONT-FAMILY:"Times New Roman","serif"'> 99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Press Release dated December 7, 2016</font></pre> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 8pt; LINE-HEIGHT:107%'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 8pt; LINE-HEIGHT:107%' align=center><font style="FONT-SIZE:11pt; LINE-HEIGHT:107%">2<b><br clear=all></b></font><b> <hr style=PAGE-BREAK-AFTER:always></b> <p /> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman","serif"'>SIGNATURES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; TEXT-INDENT:0.5in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; TEXT-INDENT:0.5in'><font style=FONT-SIZE:11pt>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; TEXT-INDENT:0.5in'>&nbsp;</p> <table width=726 bordercolor=transparent style="WIDTH:544.2pt; BORDER-COLLAPSE:collapse; MARGIN-LEFT:-0.75pt" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=181 nowrap style="HEIGHT:15pt; WIDTH:135.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">Dated: December 7, 2016</font></p></td> <td width=252 nowrap style="HEIGHT:15pt; WIDTH:188.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=28 nowrap style="HEIGHT:15pt; WIDTH:20.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=265 nowrap style="HEIGHT:15pt; WIDTH:198.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> </tr><tr style=HEIGHT:15pt> <td width=181 nowrap style="HEIGHT:15pt; WIDTH:135.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=252 nowrap style="HEIGHT:15pt; WIDTH:188.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=28 nowrap style="HEIGHT:15pt; WIDTH:20.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=265 nowrap style="HEIGHT:15pt; WIDTH:198.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <tr style=HEIGHT:15pt> <td width=181 nowrap style="HEIGHT:15pt; WIDTH:135.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=252 nowrap style="HEIGHT:15pt; WIDTH:188.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=293 colspan=2 nowrap style="HEIGHT:15pt; WIDTH:3.05in; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:11pt; COLOR:black">ITUS CORPORATION</font></b></p></td></tr> <tr style=HEIGHT:15pt> <td width=181 nowrap style="HEIGHT:15pt; WIDTH:135.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=252 nowrap style="HEIGHT:15pt; WIDTH:188.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=28 nowrap style="HEIGHT:15pt; WIDTH:20.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=265 nowrap style="HEIGHT:15pt; WIDTH:198.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> </tr><tr style=HEIGHT:15pt> <td width=181 nowrap style="HEIGHT:15pt; WIDTH:135.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=252 nowrap style="HEIGHT:15pt; WIDTH:188.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=28 nowrap style="HEIGHT:15pt; WIDTH:20.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">By:</font></p></td> <td width=265 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:198.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">/s/ Robert A. Berman</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=181 nowrap style="HEIGHT:15pt; WIDTH:135.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=252 nowrap style="HEIGHT:15pt; WIDTH:188.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=28 nowrap style="HEIGHT:15pt; WIDTH:20.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=265 nowrap style="HEIGHT:15pt; WIDTH:198.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">Name: Robert A. Berman</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=181 nowrap style="HEIGHT:15pt; WIDTH:135.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=252 nowrap style="HEIGHT:15pt; WIDTH:188.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=28 nowrap style="HEIGHT:15pt; WIDTH:20.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=265 nowrap style="HEIGHT:15pt; WIDTH:198.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">Title: President and Chief Executive Officer</font></p></td></tr></table> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 8pt; LINE-HEIGHT:107%'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 8pt; LINE-HEIGHT:107%' align=center><font style="FONT-SIZE:11pt; LINE-HEIGHT:107%">3</font></p></div></body>
<!-- EDGAR Validation Code: 0CB7ED17 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<head><title>Exhibit 99.1</title> </head> <body style="FONT-SIZE:10pt; FONT-FAMILY:'Times New Roman'; COLOR:#000000; MARGIN-TOP:0px"> <p style="FONT-SIZE:12pt; FONT-FAMILY:'Arial'; MARGIN:0px" align=right><b><u>Exhibit 99.1</u></b></p> <p style=MARGIN:0px align=center><br></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:'Arial'; MARGIN:0px" align=center><b><u>ITUS Announces Cchek</u></b><font style="FONT-FAMILY:'Symbol'"><b><u><font style="FONT-SIZE:11pt; FONT-FAMILY:Symbol">&#212;</font></font> Preliminary Cancer Patient Efficacy Study Results</u></b></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:'Arial'; MARGIN:0px" align=justify><b>LOS ANGELES, CA <font style="FONT-FAMILY:Arial Unicode MS,Arial">&#150;</font> December 7, 2016: </b>ITUS Corporation (<font style="FONT-FAMILY:Arial Unicode MS,Arial">&#147;</font><u>ITUS</u><font style="FONT-FAMILY:Arial Unicode MS,Arial">&#148;</font>) (NASDAQ: <u>ITUS</u>), today announced preliminary results from its Cchek</font><font style="FONT-SIZE:11pt; FONT-FAMILY:Symbol">&#212;</font><font style=FONT-SIZE:11pt> cancer patient efficacy study. Using its most recent protocols and methods for measuring a patient<font style="FONT-FAMILY:Arial Unicode MS,Arial">&#146;</font>s immunological response to a malignancy, the Company achieved Sensitivity of 92% and Specificity of 92% for 88 patient samples, including 54 samples from patients with multiple types and severities of cancer, and 34 healthy patients. &nbsp;During the initial phase of the study, which involved multiple experimental protocols and techniques for measuring immunological responses, the Company reviewed and analyzed data from a total of 315 patient samples, including 228 patients with varying stages of cancer, as well as blood samples from 87 healthy donors. </p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:'Arial'; MARGIN:0px" align=justify>Patient samples representing 14 different types of cancer including Breast Cancer, Lung Cancer, Colon Cancer, Melanoma, Ovarian Cancer, Liver Cancer, Thyroid Cancer, Pancreatic Cancer,&nbsp;Appendiceal Cancer (cancer of the appendix), Uterine Cancer, Osteosarcoma (cancer of the bone), Leiomyosarcoma (cancer of the soft tissue), Liposarcoma (cancer of the connective tissue), and Vulvar Cancer (cancer of the Vulva) were included in the study. The study included samples from patients with early and late stage, biopsy-verified, drug-na&#239;ve (before therapy) tumors, as well as biopsy-verified, refractory (unresponsive to attempted chemotherapy) tumors. </p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:'Arial'; MARGIN:0px" align=justify>Sensitivity and specificity are scientific measurements commonly used to determine the accuracy of a diagnostic test, where sensitivity measures how good a test is at identifying people with a particular disease, and specificity measures how good a test is at identifying people without the disease. Although published results vary widely, established diagnostic tests such as Low Dose Computed Tomography (LDCT), which is used to screen for Lung Cancer, has sensitivity of approximately 93% and specificity of approximately 73%; the Prostate Specific Antigen (<font style="FONT-FAMILY:Arial Unicode MS,Arial">&#147;</font>PSA<font style="FONT-FAMILY:Arial Unicode MS,Arial">&#148;</font>) test, which is used to screen for prostate cancer, has sensitivity of approximately 21% and specificity of approximately 91%; and Mammography, used to screen for breast cancer and considered to be the <font style="FONT-FAMILY:Arial Unicode MS,Arial">&#147;</font>gold standard<font style="FONT-FAMILY:Arial Unicode MS,Arial">&#148;</font> for breast cancer screening, has reported sensitivity as low as 68% and specificity as low as 75%. As these results indicate, current diagnostic testing is hampered by low sensitivity, low specificity, or both, meaning that the tests miss a substantial portion of the cancers they are supposed to detect, or misdiagnose a large number of healthy patients as having cancer. There is currently no inexpensive, non-invasive diagnostic test that excels in both sensitivity and specificity. These preliminary results, while extremely promising, will have to be confirmed in blinded clinical studies of sufficient size, and benign conditions will have to be evaluated, before we can seek marketing approval for Cchek<font style="FONT-FAMILY:Arial Unicode MS,Arial">&#153;</font> from the FDA.</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:'Arial'; MARGIN:0px" align=justify><br></p> <hr> <div style=PAGE-BREAK-BEFORE:always>&nbsp;</div> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:'Arial'; MARGIN:0px" align=justify>Initial samples in the study were tested utilizing immunostaining and fluorescent microscopic imaging. While results were promising, subjectivity in interpreting the imaging results together with labor-intensive and time-consuming sample processing hampered the commercial viability of this approach. Subsequently, patient samples were analyzed using flow cytometry, enabling more efficient processing and analysis. &nbsp;In addition, ITUS is developing a software application using a proprietary neural network, which currently relies on up to 13 quantitative parameters to analyze test results. This approach, which is highly data-intensive and requires substantial computer processing power to develop, results in a test which can be performed on a desktop computer. An initial version of our unique neural network, which was trained to distinguish between the immunological responses of cancer patients and healthy patients, was responsible for the sensitivity and specificity results reported above. The Company will continue to improve its protocols, continue to upgrade its neural network software by increasing the number of patient samples used to train the software and expanding the range of markers, increasing the data resolution, and enhancing the architecture of the software, which may enable better results.</p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:'Arial'; MARGIN:0px" align=justify>ITUS<font style="FONT-FAMILY:Arial Unicode MS,Arial">&#146;</font>s approach to identifying the presence of cancer is to monitor subtle changes in blood which are indicative of immune function. During tumor growth, there is a dramatic increase in the number and types of immune cells within the tumor microenvironment (TME). The study of the functions of these immune cells in the TME, and the ability to modify these functions has given rise to the breakthrough immunotherapy drugs that are starting to appear on the market. ITUS<font style="FONT-FAMILY:Arial Unicode MS,Arial">&#146;</font>s Cchek<font style="FONT-SIZE:11pt; FONT-FAMILY:Symbol">&#212;</font><font style=FONT-SIZE:11pt> diagnostic platform focuses on a subset of these cells that seem to appear at the earliest formation of a tumor, and which spill into the vasculature from the TME. By using proprietary protocols and fluorescently labeled antibodies, Cchek<font style="FONT-SIZE:11pt; FONT-FAMILY:Symbol">&#212;</font><font style=FONT-SIZE:11pt> sorts and counts the rare and specific cells. Multiparametric analysis of the cells is conducted using the noted neural network software application. ITUS has been successful in corroborating diagnoses for 14 different types of cancer, and in accurately distinguishing the blood of cancer patients from the blood of heathy individuals.</p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:'Arial'; MARGIN:0px" align=justify>A substantial portion of the samples in the study came from biopsy verified breast cancer patients. In the U.S., approximately 40 million women receive screening mammograms each year. Studies indicate that: for most women, mammograms miss approximately 20% of breast cancers; for women with dense breasts, which account for 40% to 50% of all women, mammograms miss as much as 50% of breast cancers; approximately 11% of all women receiving mammograms are called back for what are known as <font style="FONT-FAMILY:Arial Unicode MS,Arial">&#147;</font>false positives,<font style="FONT-FAMILY:Arial Unicode MS,Arial">&#148;</font> requiring additional confirmatory testing which can be invasive and painful; and on average, only 1 out of 20 women called back for follow-on testing ends up having breast cancer. Based upon our preliminary results, as a confirmatory diagnostic test for </p> <p style=MARGIN:0px align=justify><br><br></p> <hr> <div style=PAGE-BREAK-BEFORE:always>&nbsp;</div> <p style="FONT-SIZE:12pt; FONT-FAMILY:'Arial'; MARGIN:0px" align=justify>breast cancer, Cchek<font style="FONT-SIZE:11pt; FONT-FAMILY:Symbol">&#212;</font><font style=FONT-SIZE:11pt> has the potential to significantly reduce the need for invasive follow-on procedures such as needle biopsies, and could also be used to detect cancers missed by conventional mammograms, including for women with dense breast tissue. While we have not yet studied the impact of dense breast tissue on Cchek<font style="FONT-SIZE:11pt; FONT-FAMILY:Symbol">&#212;</font><font style=FONT-SIZE:11pt> results, because Cchek</font><font style="FONT-SIZE:11pt; FONT-FAMILY:Symbol">&#212;</font><font style=FONT-SIZE:11pt> measures the immunological response to cancer and does not rely on imaging, the Company expects that if Cchek<font style="FONT-SIZE:11pt; FONT-FAMILY:Symbol">&#212;</font><font style=FONT-SIZE:11pt> was developed and commercialized as a confirmatory diagnostic test for breast cancer, it would be much better at detecting breast cancer in women with dense breasts than a conventional mammogram. The Company has not yet determined whether Cchek<font style="FONT-SIZE:11pt; FONT-FAMILY:Symbol">&#212;</font><font style=FONT-SIZE:11pt> will initially be directed at cancer screening or confirmatory diagnostic testing, and for which type or types of cancer. The Company will make those decisions after further development and testing, and prior to seeking initial regulatory approval. The Company expects to eventually use Cchek<font style="FONT-SIZE:11pt; FONT-FAMILY:Symbol">&#212;</font><font style=FONT-SIZE:11pt> as a platform to launch multiple tests across multiple markets. </p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:'Arial'; MARGIN:0px" align=justify>ITUS has submitted its data for presentation at upcoming scientific meetings, and will eventually submit its data for publication. Next steps include continuing to process additional patient samples, testing additional types of cancers, evaluating benign conditions, conducting double-blinded testing and preparing for constructive discussions with the US Food and Drug Administration regarding the most efficient regulatory approval path.</p> <p style=MARGIN:0px align=justify><br></p> <p style="MARGIN-BOTTOM:8px; FONT-FAMILY:'Arial'; MARGIN-TOP:0px" align=justify><b>ITUS Corporation</b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:'Arial'; MARGIN:0px" align=justify><u>ITUS</u> Corporation is developing a platform called Cchek<font style="FONT-SIZE:11pt; FONT-FAMILY:Symbol">&#212;</font><font style=FONT-SIZE:11pt>, a series of non-invasive, blood tests for the early detection of solid tumor based cancers, which is based on the body<font style="FONT-FAMILY:Arial Unicode MS,Arial">&#146;</font>s immunological response to the presence of a malignancy. &nbsp;Additional information is available at <u>www.ITUScorp.com</u>.</p> <p style="MARGIN-BOTTOM:8px; MARGIN-TOP:0px" align=justify># # #</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:'Arial'; MARGIN:0px" align=justify><strong>Forward-Looking Statements:</b></strong> <font style="FONT-FAMILY:Arial">Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect ITUS Corporation's current expectations concerning future events and results. We generally use the words <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>believes,<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font> <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>expects,<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font> <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>intends,<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font> <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>plans,<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font> <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>anticipates,<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font> <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>likely,<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font> <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>will<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font> and similar expressions to identify forward-looking statements. &nbsp;Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. &nbsp;These risks, uncertainties and factors include, but are not limited to, those factors set forth in <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>Item 1A <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#150;</font> Risk Factors<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font> and other sections of our Annual Report on Form 10-K for the fiscal year ended October 31, 2016 as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. &nbsp;We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. &nbsp;You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. </font></p> <br><p style="FONT-FAMILY:Breuer Text Medium,Times New Roman; MARGIN:0px">Contact:<br>Dean Krouch<br>310-484-5184</p> <p style="FONT-FAMILY:Breuer Text Medium,Times New Roman; MARGIN:0px" align=justify><u>dkrouch@ITUScorp.com</u> </p> <p style="MARGIN-BOTTOM:9px; MARGIN-TOP:0px" align=justify><br></p> <p style="MARGIN-BOTTOM:8px; FONT-FAMILY:Breuer Text Medium,Times New Roman; MARGIN-TOP:0px" align=justify>&nbsp;<u>ITUS Corporation</u><u>:</u> FOCUSED ON INNOVATION<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#153;</font></p> <p style="MARGIN-BOTTOM:8px; MARGIN-TOP:0px" align=justify><br><br></p></body>
<!-- EDGAR Validation Code: 845722CD -->
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
